TD
MCID: TRD006
MIFTS: 49

Tardive Dyskinesia (TD) malady

Categories: Rare diseases, Neuronal diseases, Oral diseases

Aliases & Classifications for Tardive Dyskinesia

About this section

Aliases & Descriptions for Tardive Dyskinesia:

Name: Tardive Dyskinesia 48 49 27 68
Neuroleptic-Induced Tardive Dyskinesia 68
Lingual-Facial-Buccal Dyskinesia 68
Drug-Induced Tardive Dyskinesia 68
 
Linguofacial Dyskinesia 48
Tardive Oral Dyskinesia 48
Tardive Dystonia 48
Td 48

Characteristics:


Classifications:



Summaries for Tardive Dyskinesia

About this section
NIH Rare Diseases:48 Tardive dyskinesia is a neurological movement disorder that is caused by the long-term use of a certain type of medications called neuroleptics. neuroleptic drugs are usually prescribed for psychiatric conditions, although they may be used to treat gastrointestinal or neurological conditions in some cases. tardive dyskinesia is primarily characterized by repetitive involuntary movements of the jaw, lips and tongue such as grimacing; sticking out the tongue; and smacking, puckering and pursing the lips. some affected people may also experience involuntary rapid, jerking movements (chorea) or slow, writhing movements (athetosis) of the arms and/or legs. it is unclear why some people who take neuroleptic medications develop these symptoms while others do not. treatment for this condition varies but may include stopping or minimizing the use of neuroleptic drugs and/or taking additional medications to to reduce the severity of the symptoms. last updated: 12/18/2014

MalaCards based summary: Tardive Dyskinesia, also known as neuroleptic-induced tardive dyskinesia, is related to schizophrenia and drug induced dyskinesia, and has symptoms including spasmodic torticollis, myoclonus and myoclonus. An important gene associated with Tardive Dyskinesia is NQO1 (NAD(P)H Quinone Dehydrogenase 1), and among its related pathways are Oxidative Stress and DARPP-32 Phosphorylation. Affiliated tissues include tongue, eye and brain, and related mouse phenotypes are digestive/alimentary and liver/biliary system.

NINDS:49 Tardive dyskinesia is a neurological syndrome caused by the long-term use of neuroleptic drugs. Neuroleptic drugs are generally prescribed for psychiatric disorders, as well as for some gastrointestinal and neurological disorders. Tardive dyskinesia is characterized by repetitive, involuntary, purposeless movements. Features of the disorder may include grimacing, tongue protrusion, lip smacking, puckering and pursing, and rapid eye blinking. Rapid movements of the arms, legs, and trunk may also occur. Involuntary movements of the fingers may be present.

Wikipedia:71 Tardive dyskinesia (TD) is a difficult-to-treat and often incurable form of dyskinesia, a disorder... more...

Related Diseases for Tardive Dyskinesia

About this section

Diseases related to Tardive Dyskinesia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 70)
idRelated DiseaseScoreTop Affiliating Genes
1schizophrenia30.2BDNF, CYP1A2, CYP2D6, DRD2, DRD3, HTR2A
2drug induced dyskinesia11.4
3dystonia10.4
4sphenoorbital meningioma10.2DRD2, DRD3
5intracranial aneurysm10.2DRD2, DRD3
6c8 deficiency, type ii10.2DRD2, DRD3
7splenic abscess10.1DRD2, HTR2A
8euthyroid sick syndrome10.1DRD2, HTR2A
9waardenburg's syndrome10.1DRD2, HTR2A
10mood disorder10.1
11neuronitis10.1
12chorea gravidarum10.0CYP2D6, DRD2
13pyromania10.0DRD2, DRD3, HTR2A
14allergic hypersensitivity disease10.0DRD2, HTR2A
15cecal benign neoplasm10.0DRD2, DRD3, HTR2A
16hypoglycemia10.0BDNF, DRD2, DRD3
17alopecia10.0BDNF, DRD2, DRD3
18vascular cancer10.0DRD2, HTR2A
19intrahepatic gall duct cancer10.0BDNF, HTR2A
20microcephaly 13, primary, autosomal recessive10.0DRD2, DRD3, HTR2A
21ischemic neuropathy10.0CYP2D6, DRD2, DRD3
22bipolar disorder10.0
23dementia10.0
24hypothyroidism10.0
25intellectual disability10.0
26urea cycle disorder10.0BDNF, DRD2
27multiple personality disorder10.0BDNF, HTR2A
28postencephalitic parkinson disease9.9BDNF, DRD2, HTR2A
29hereditary multiple exostoses9.9BDNF, DRD2, HTR2A
30trichomegaly9.9CYP1A2, CYP2D6
31benign epilepsy with centrotemporal spikes9.9BDNF, DRD2, HTR2A
32gas gangrene9.9CYP1A2, CYP2D6
33keratosis9.9BDNF, CYP2D6, HTR2A
34tinea pedis9.9CYP1A2, CYP2D6
35hypoglycemic coma9.8BDNF, HTR2A
36cytomegalic congenital adrenal hypoplasia9.8BDNF, DRD2, DRD3, HTR2A
37epithelioid type angiomyolipoma9.8BDNF, CYP2D6, HTR2A
38brain glioblastoma multiforme9.8BDNF, DRD2, DRD3, HTR2A
39huntington disease9.8
40choreoacanthocytosis9.8
41gilles de la tourette syndrome9.8
42cataract9.8
43hepatitis9.8
44rocky mountain spotted fever9.8
45anosognosia9.8
46spotted fever9.8
47megacolon9.8
48olecranon bursitis9.8
49bipolar i disorder9.8
50cervicitis9.8

Comorbidity relations with Tardive Dyskinesia via Phenotypic Disease Network (PDN):


Alzheimer DiseaseAnxiety Disorder
Bipolar DisorderDeficiency Anemia
Dysthymic DisorderHypothyroidism
Paranoid SchizophreniaParkinson Disease, Late-Onset
Protein-Energy MalnutritionSchizophrenia
Schizophreniform DisorderAcute Cystitis
Decubitus UlcerEsophagitis
Hypertension, Essential

Graphical network of the top 20 diseases related to Tardive Dyskinesia:



Diseases related to tardive dyskinesia

Symptoms & Phenotypes for Tardive Dyskinesia

About this section

Human phenotypes related to Tardive Dyskinesia:

 64
id Description HPO Frequency HPO Source Accession
1 abnormality of the nervous system64 HP:0000707
2 tardive dyskinesia64 HP:0040141

UMLS symptoms related to Tardive Dyskinesia:


spasmodic torticollis, myoclonus

MGI Mouse Phenotypes related to Tardive Dyskinesia according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053819.0BDNF, DRD2, DRD3, HSPG2, HTR2A
2MP:00053708.1CYP1A2, DRD2, HSPG2, NQO1, SOD2
3MP:00053867.8BDNF, CYP1A2, DRD2, DRD3, HSPG2, HTR2A

Drugs & Therapeutics for Tardive Dyskinesia

About this section

Drugs for Tardive Dyskinesia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 91)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Risperidoneapproved, investigationalPhase 4, Phase 3, Phase 1492106266-06-25073
Synonyms:
106266-06-2
3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido(1,2-a)pyrimidin-4-one
3-(2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl)-2-methyl-6,7,8,9-tetrahydro-pyrido[
3-(2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl)-2-methyl-6,7,8,9-tetrahydropyrido[1,
3-[2-[-4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido [1,2-a] pyrimidin-4-one
3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperi-dino]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]-pyrimidin-4-one
3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,
3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
AB00514010
AC-1306
AC1L1JJU
BIDD:GT0262
BRD-K53857191-001-04-5
BRN 4891881
Belivon
Bio-0092
Buspirone
C23H27FN4O2
CAS-106266-06-2
CHEBI:8871
CHEMBL85
CID5073
CPD000466323
Consta, Risperdal
D00426
D018967
DB00734
EU-0101074
HMS1571M19
HMS2051H07
HMS2089C22
HSDB 7580
I01-1156
Jsp000573
KS-1106
L000510
LS-134196
Lopac-R-118
MLS000759429
MLS001165758
MLS001424081
MolPort-002-885-858
 
NCGC00015883-01
NCGC00015883-02
NCGC00015883-03
NCGC00094352-01
NCGC00094352-02
NCGC00094352-03
NCGC00179257-01
Prestwick0_001029
Prestwick1_001029
R 62 766
R 64 766, Risperdal, Risperidone
R 64,766
R 64766
R-118
R-64,766
R-64-766
R-64766
R64,766
R64766
Rispen
Risperdal
Risperdal (TN)
Risperdal Consta
Risperdal M-Tab
Risperidal
Risperidal M-Tab
Risperidona
Risperidona [Spanish]
Risperidone
Risperidone (JAN/USAN/INN)
Risperidone (RIS)
Risperidone [USAN:BAN:INN]
Risperidone, placebo
Risperidonum
Risperidonum [Latin]
Risperin
Rispolept
Rispolin
S1615_Selleck
SAM001246595
SMR000466323
SPBio_003078
STK646402
Sequinan
Spiron
TL8000230
UNII-L6UH7ZF8HC
risperdone
risperidone
2
DopamineapprovedPhase 4, Phase 3, Phase 1383651-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
3ZotepineapprovedPhase 4326615-21-4
4
ZolpidemapprovedPhase 410482626-48-05732
Synonyms:
2C19H21N3O
82626-48-0
AC1L1L0K
Ambien
BIDD:GT0785
BRD-K44876623-001-01-1
BSPBio_002278
C07219
CHEBI:10125
CHEMBL911
CID5732
D08690
DB00425
DEA No. 2783
HMS1922F22
Hypnogen
I06-0128
LS-187761
LS-80196
Lorex
MolPort-003-666-656
Myslee
N,N,6-Trimethyl-2-(4-methylphenyl)-imidazo[1,2-a]pyridine-3-acetamide
N,N,6-Trimethyl-2-(4-methylphenyl)imidazo(1,2-a)pyridine-3-acetamide
N,N,6-Trimethyl-2-p-tolylimidazo[1,2-a]pyridine-3-acetamide
 
N,N,6-trimethyl-2-(4-methylphenyl)imidazo(1,2a)pyridine-3-acetamide hemitartrate
N,N-Dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide
NCGC00095179-01
NCGC00095179-02
NCGC00095179-03
NCGC00095179-04
SL 80.0750
SL-800750
SL-800750-23-N
SPECTRUM1505369
STK627113
Sanval
Sanval (TN)
Stilnoct
Stilnox
UNII-7K383OQI23
Z103_SIGMA
ZINC00003876
Zolpidem
Zolpidem (INN)
Zolpidem Ambien
Zolpidem [INN:BAN]
Zolpidem tartrate
Zolpidemum
Zolpidemum [Latin]
zolpidem
5
Aripiprazoleapproved, investigationalPhase 4358129722-12-960795
Synonyms:
129722-12-9
24-29-3
7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydro-2(1H)-quinolinone
7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydrocarbostyril
7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butyloxy)-3,4-dihydro-2(1H)-quinolinone
7-[4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril
7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one
7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1H)-one
AC-1554
AC1L1TXZ
AC1Q3T38
ALKS-9070
Abilify
Abilify (TN)
Abilify Discmelt
Abilitat
Aripiprazol
Aripiprazole
Aripiprazole (JAN/USAN/INN)
Aripiprazole [USAN]
Aripiprazolum
Aripirazole
Arpizol
Asprito|
BMS-337039
Bio-0004
Bristol-Myers Squibb brand of aripiprazole
C094645
C12564
C23H27Cl2N3O2
CHEBI:31236
CHEMBL1112
CID60795
CPD000466383
 
D01164
DB01238
Discmelt
FT-0082572
HMS2051I18
HMS2089M20
HMS2093F22
HSDB 7320
KS-1030
L001339
LS-142666
MLS000759517
MLS001165779
MLS001195621
MLS001424078
MolPort-002-885-808
MolPort-003-844-657
NCGC00159510-02
NCGC00159510-03
OPC 31
OPC-14597
OPC-31
Opc 14597
Otsuka brand of aripiprazole
Pripiprazole
S06-0010
SAM001246750
SMR000466383
STK625160
TL8000707
TL80090184
UNII-82VFR53I78
aripiprazol
aripiprazole
aripiprazolum
||OPC 14597
6
BenzocaineapprovedPhase 420161994-09-7, 94-09-72337
Synonyms:
(p-(Ethoxycarbonyl)phenylamine
06952_FLUKA
112909_ALDRICH
112909_SIAL
1333-08-0
23239-88-5
23239-88-5 (hydrochloride)
4 Aminobenzoic Acid Ethyl Ester
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-14-00-01129 (Beilstein Handbook Reference)
4-Aminobenzoate
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Aminobenzoic acid, ethyl ester
4-Carbethoxyaniline
4-amino-benzoic acid ethyl ester
4-aminobenzoic acid ethyl ester
71123-91-6
94-09-7
94-09-7 (Parent)
A0271
AB00051923
AC1L1DGC
AC1Q341A
AC1Q64JE
AE-562/40377256
AI3-02081
AKOS000119763
AR-1H9065
Acetate, Benzocaine
Aethoform
Aethylium paraminobenzoicum
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthesinum
Anaesthin
Anestezin
Anestezin [Russian]
Anesthesin
Anesthesine
Anesthone
BB_SC-0019
BPBio1_001017
BRD-K75466013-001-05-2
BRN 0638434
BSPBio_000923
BSPBio_001908
Baby Anbesol
Bensokain
Benzoak
Benzocaina
Benzocaina [INN-Spanish]
Benzocaine
Benzocaine (USP/INN)
Benzocaine Acetate
Benzocaine Formate
Benzocaine Hydrobromide
Benzocaine Hydrochloride
Benzocaine Methanesulfonate
Benzocaine [INN:BAN]
Benzocainum
Benzocainum [INN-Latin]
Benzoic acid, 4-amino-, ethyl ester
Benzoic acid, 4-amino-, ethyl ester, hydrochloride
Benzoic acid, amino-, ethyl ester
Benzoic acid, p-amino-, ethyl ester
C07527
CAS-94-09-7
CHEBI:116735
CHEMBL278172
CID2337
Caswell No. 430A
Chloraseptic
D001566
D00552
DB01086
Dermoplast
Diet Ayds
DivK1c_000932
E1501_SIGMA
EINECS 202-303-5
EPA Pesticide Chemical Code 097001
ETHYL-P-AMINOBENZOATE
Ethoform
Ethoforme
Ethyl 4-aminobenzoate
Ethyl 4-aminobenzoate hydrochloride
Ethyl 4-aminobenzoic acid
Ethyl Aminobenzoate
Ethyl PABA
 
Ethyl aminobenzoate
Ethyl aminobenzoate (JP15)
Ethyl aminobenzoate (VAN)
Ethyl aminobenzoic acid
Ethyl p-Aminobenzoate
Ethyl p-Aminophenylcarboxylate
Ethyl p-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethylester kyseliny p-aminobenzoove
Ethylester kyseliny p-aminobenzoove [Czech]
Ethylis aminobenzoas
Formate, Benzocaine
HMS1570O05
HMS1920G09
HMS2091M11
HMS502O14
HSDB 7225
Hurricaine
Hydrobromide, Benzocaine
Hydrochloride, Benzocaine
I05-0204
IDI1_000932
Identhesin
KBio1_000932
KBio2_000474
KBio2_003042
KBio2_005610
KBio3_001408
KBioGR_000658
KBioSS_000474
Keloform
LS-35847
MLS001331704
MLS002153970
Methanesulfonate, Benzocaine
MolPort-000-871-526
NCGC00016352-01
NCGC00094598-01
NCGC00094598-02
NINDS_000932
NSC 122792
NSC 41531
NSC41531
NSC4688
Norcain
Norcaine
Norcainum
Oprea1_750694
Oprea1_827402
Ora-jel
Orabase-B
Orthesin
Otocain
Outgro
Parathesin
Parathesin (TN)
Parathesine
Prestwick0_000712
Prestwick1_000712
Prestwick2_000712
Prestwick3_000712
Prestwick_991
SMR000059025
SPBio_000134
SPBio_002844
SPECTRUM1500139
STK043620
Slim Mint Gum
Solarcaine
Solu H
Spectrum2_000117
Spectrum3_000314
Spectrum4_000249
Spectrum5_000860
Spectrum_000074
Topcaine
UNII-U3RSY48JW5
WLN: ZR DVO2
ZINC12358719
benzocaine
ethylaminobenzoate-4
h-4-abz-oet
nchembio.182-comp4
p-(Ethoxycarbonyl)aniline
p-Aminobenzoate
p-Aminobenzoic acid
p-Aminobenzoic acid ethyl ester
p-Aminobenzoic acid, ethyl ester
p-Aminobenzoic ethyl ester
p-Carbethoxyaniline
p-Ethoxycarboxylic Aniline
p-Ethoxycarboxylic aniline
7
BupropionapprovedPhase 432934841-39-9, 34911-55-2444
Synonyms:
( -)-2-(tert-Butylamino)-3'-chloropropiophenone
( -)-2-(tert-Butylamino)-3'-chlorpropiophenon
(+-)-1-(3-chlorophenyl)-2-((1,1-dimethylethyl)amino)-1-propanone
(+-)-Bupropion
.alpha.-(tert-Butylamino)-m-chloropropiophenone
1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]propan-1-one
2-(Tert-Butylamino)-3'-chloropropiophenone
2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one
34841-36-6 (hydrochloride)
34841-39-9
34911-55-2
AB00053756
AC-197
AC1L198Y
AMFEBUTAMONE HCl
Amfebutamon
Amfebutamona
Amfebutamona [INN-Spanish]
Amfebutamone
Amfebutamonum
Amfebutamonum [INN-Latin]
BPBio1_000042
BRD-A05186015-003-05-7
BRN 2101062
BSPBio_000038
BSPBio_002247
Bupropion (INN)
Bupropion (Old RN)
Bupropion (USAN)
Bupropion Hcl
Bupropion SR
Bupropion [INN:BAN]
Bupropion hydrocloride
C06860
CHEBI:3219
CHEMBL894
CID444
CPD000472526
D07591
DB01156
DivK1c_007050
Elont
 
HMS2051G10
HMS2089G14
Jsp006301
KBio1_001994
KBio2_002143
KBio2_004711
KBio2_007279
KBio3_001467
KBioGR_001168
KBioSS_002143
L000725
LS-122817
Lopac0_000166
MLS001424015
MolPort-003-845-432
NCGC00015122-06
NCGC00089751-02
NCI60_002714
NSC315851
Prestwick0_000249
Prestwick1_000249
Prestwick2_000249
Prestwick3_000249
SAM001246699
SMR000472526
SPBio_001817
SPBio_002257
SpecPlus_000954
Spectrum2_001659
Spectrum3_000644
Spectrum4_000614
Spectrum5_001406
Spectrum_001663
TL8002604
UNII-01ZG3TPX31
Wellbatrin
Wellbutrin
Wellbutrin SR
Wellbutrin XL
Zyban
alpha-(tert-butylamino)-m-chloropropiophenone
amfebutamonum
bupropion
8
ZiprasidoneapprovedPhase 4145146939-27-760854
Synonyms:
138982-67-9 (hydrochloride monohydrate)
146939-27-7
5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one
5-{2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one
5-{2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one
6-chloro-5-[2-[4-(7-thia-8-azabicyclo[4.3.0]nona-1,3,5,8-tetraen-9-yl)piperazin-1-yl]ethyl]-1,3-dihydroindol-2-one
AC1L1U27
Ambap122883-93-6
BIDD:GT0042
C07568
C21H21ClN4OS
CHEBI:10119
CHEMBL708
CID60854
CP 88059
CP 88059-01
CP-88,059
CP-88,059-01
CP-88,059-1
CP-88059-1
CPD000466328
D08687
DB00246
 
Geodon
Geodon Oral
I14-0766
L000659
LS-83744
MLS000759435
MolPort-003-850-885
SAM001246607
SMR000466328
TL8000889
UNII-6UKA5VEJ6X
Zeldox
Zipradon
Zipradon (TN)
Ziprasidona
Ziprasidone
Ziprasidone (INN)
Ziprasidone [INN:BAN]
Ziprasidone hydrochloride
Ziprasidone mesylate trihydrate
Ziprasidonum
ziprasidona
ziprasidonum
ziprazidone
9
NicotineapprovedPhase 4110354-11-5942, 89594
Synonyms:
(−
(+)-Nicotine
(-)-3-(1-Methyl-2-pyrrolidyl)pyridine
(-)-3-(N-Methylpyrrolidino)pyridine
(-)-Nicotine
(-)-Nicotine solution
(2S) 3-(1-Methyl-pyrrolidin-2-yl)-pyridine
(R)-3-(1-Methyl-2-pyrrolidinyl)pyridine
(R,S)-Nicotine
(S)-(-)-NICOTINE, 3-[(2S)-1-METHYL-2-PYRROLIDINYL] PYRIDINE
(S)-(-)-Nicotine
(S)-(−)-nicotine
(S)-3-(1-methylpyrrolidin-2-yl)pyridine
(S)-3-(N-methylpyrrolidin-2-yl)pyridine
(S)-Nicotine
(−)-nicotine
)-1-Methyl-2-(3-pyridyl)pyrrolidine
)-Nicotine
)-Nicotine solution
1-Methyl-2-(3-pyridal)-Pyrrolidine
1-Methyl-2-(3-pyridal)-pyrrolidene
1-Methyl-2-(3-pyridiyl)pyrrolidine
1-Methyl-2-(3-pyridyl)pyrrolidine
1uw6
2'-beta-H-Nicotine
3-(1-Methyl-2-pyrollidinyl)pyridine
3-(1-Methyl-2-pyrrolidinyl)-Pyridine
3-(1-Methyl-2-pyrrolidinyl)pyridine
3-(1-Methylpyrrolidin-2-yl)pyridine
3-(2-(N-methylpyrrolidinyl))pyridine
3-(N-Methylpyrollidino)pyridine
3-(N-Methylpyrrolidino)pyridine
3-(N-methylpyrollidino)pyridine
3-N-Methylpyrrolidine
3-[(2S)-1-methylpyrrolidin-2-yl]pyridine
36733_FLUKA
36733_RIEDEL
434F7990-3240-4A43-ACEC-E6CC1E495FA0
46343_FLUKA
46343_RIEDEL
54-11-5
AC1L3I79
AC1Q3ZOC
AI3-03424
BB_NC-0777
BIDD:GT0599
BRD-K05395900-322-02-1
Black Leaf
Black Leaf 40
C00745
CCRIS 1637
CHEBI:17688
CHEMBL3
CID89594
CPD000059074
Campbell's Nico-Soap
Caswell No. 597
Commit
D-Nicotine
D03365
DL-tetrahydronicotyrine
Destruxol
Destruxol Orchid Spray
EINECS 200-193-3
ENT 3,424
EPA Pesticide Chemical Code 056702
Emo-Nik
Flux Maag
Fumeto bac
Fumetobac
HSDB 1107
Habitrol
Habitrol (TN)
L(-)-nicotine
L(−)-nicotine
L-3-(1-Methyl-2-pyrrolidyl)pyridine
 
L-Nicotine
LS-202
MLS001055457
MLS001335905
Mach-Nic
Methyl-2-pyrrolidinyl)pyridine
Micotine
MolPort-000-744-731
N3876_SIGMA
N5511_FLUKA
N5511_SIGMA
NCGC00090693-01
NCGC00090693-02
NCGC00090693-03
NCGC00090693-04
NCGC00090693-05
NCGC00090693-06
NCGC00090693-07
NCT
NICOTINE AND SALTS
NSC 5065
NSC97238
Niagara P.A. Dust
Nic-Sal
Nico-Dust
Nico-Fume
Nicocide
Nicoderm
Nicoderm Cq
Nicoderm Patch
Nicorette
Nicorette Plus
Nicotin
Nicotina
Nicotina [Italian]
Nicotine
Nicotine (USP)
Nicotine (compounds related to)
Nicotine Alkaloid
Nicotine Patch
Nicotine Polacrilex
Nicotine [BSI:ISO]
Nicotine [UN1654]
Nicotine [UN1654] [Poison]
Nicotine [USAN]
Nicotrol
Nicotrol Inhaler
Nicotrol Ns
Nictoine patch
Nikotin
Nikotin [German]
Nikotyna
Nikotyna [Polish]
Ortho N-4 Dust
Ortho N-5 Dust
PDSP1_000113
PDSP1_000465
PDSP2_000463
PDSP2_000555
Prostep
R)-(+)-Nicotine
RCRA waste no. P075
RCRA waste number P075
SAM002564224
SDCCGMLS-0066911.P001
SMR000059074
Tendust
Transdermal Nicotine
UN1654
a -N-Methylpyrrolidine
a-N-Methylpyrrolidine
alpha-N-Methylpyrrolidine
beta-Pyridyl-alpha-N-methyl pyrrolidine
beta-Pyridyl-alpha-N-methylpyrrolidine
bmse000105
delta-Nicotine
nicotine
nicotine replacement patch
10
Olanzapineapproved, investigationalPhase 4, Phase 3, Phase 1399132539-06-14585
Synonyms:
132539-06-1
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methyl-1-piperazinyl)-10 H -thieno[2,3- b ] [1,5]benzodiazepine
2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[3,2-c][1,5]benzodiazepine
AC-665
AC1L1IHS
AKOS000282888
ALKS-7921
BIDD:GT0332
BIDD:PXR0138
Bio-0169
C07322
C076029
C17H20N4S
CHEBI:7735
CHEMBL715
CID4585
CPD000466345
D00454
DB00334
Eli Lilly brand of olanzapine
HMS2051H05
HMS2089M04
HMS2093I04
I06-0784
InChI=1/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H
InChI=1/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3
Jsp001969
KS-1090
L000455
L005958
LS-152313
LY 170053
LY-170052
 
LY-170053
Lanzac
Lilly brand of olanzapine
MLS000759457
MLS001165781
MLS001195646
MLS001424057
Midax
MolPort-002-885-845
MolPort-003-666-569
MolPort-005-977-341
NCGC00096077-01
NCGC00096077-03
NCGC00096077-04
Olansek
Olanzapin
Olanzapina
Olanzapine
Olanzapine (JAN/USAN/INN)
Olanzapine (OLA)
Olanzapine [USAN:INN]
Olanzapinum
S2493_Selleck
SAM001246652
SMR000466345
SPECTRUM1505024
STK634338
Symbyax
TL8000772
UNII-N7U69T4SZR
Zalasta
Zydis
Zyprexa
Zyprexa (TN)
Zyprexa Intramuscular
Zyprexa Velotab
Zyprexa Zydis
olanzapina
olanzapine
olanzapinum
11
GalantamineapprovedPhase 4106357-70-09651, 908828, 9651
Synonyms:
(-)-Galanthamine
(4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol
1551-02-6
1953-04-4
1dx6
1qti
357-70-0
4-27-00-02184 (Beilstein Handbook Reference)
736-79-8
AC-20240
AC1L1TIM
BIDD:GT0517
BPBio1_000480
BRD-K49481516-004-03-5
BRD-K49481516-004-04-3
BRN 0093736
BSPBio_000436
BSPBio_003416
C08526
CHEBI:42944
CHEMBL659
CID9651
D04292
DivK1c_000590
GNT
Galantamin
Galantamina
Galantamina [INN-Spanish]
Galantamine
Galantamine (USAN/INN)
Galantamine [USAN:INN]
Galantaminum
Galantaminum [INN-Latin]
Galanthamine
Galanthamine hydrobromide
Galanthaminum
 
HMS2089H03
HSDB 7361
IDI1_000590
InChI=1/C17H21NO3/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(10-18)15(16)17/h3-6,12,14,19H,7-10H2,1-2H3/t12-,14-,17-/m0/s1
Jilkon
KBio1_000590
KBio2_001751
KBio2_004319
KBio2_006887
KBio3_002636
KBioGR_001417
KBioSS_001751
LS-71039
Lycoremin
Lycoremine
MolPort-002-521-885
NCGC00024731-02
NINDS_000590
NSC 100058
Prestwick0_000588
Prestwick1_000588
Prestwick2_000588
Prestwick3_000588
Probes1_000055
Probes2_000395
Razadyne ER
Reminyl
Reminyl (TN)
SDCCGMLS-0066737.P001
SMP1_000131
SPBio_002655
STOCK1N-46108
Spectrum3_001738
Spectrum4_000839
Spectrum5_001673
Spectrum_001271
UNII-0D3Q044KCA
galanthamine
12
Chlorpromazineapproved, vet_approvedPhase 41850-53-32726
Synonyms:
10-(3-Dimethylaminopropyl)-2-chlorophenothiazine
10H-Phenothiazine-10-propanamine, 2-chloro-N,N-dimethyl-, radical ion(1+)
2-Chloro-10-(3-(dimethylamino)propyl)phenothiazine
2-Chloro-10-[3-(dimethylamino)propyl]phenothiazine
2-Chloropromazine
2-Cloro-10 (3-dimetilaminopropil)fenotiazina
2-Cloro-10 (3-dimetilaminopropil)fenotiazina [Italian]
2-chloro-10-(3-(dimethylamino)propyl)-phenothiazine
2-chloro-N,N-dimethyl-10H-Phenothiazine-10-propanamine
2601A
3-(2-Chloro-10H-phenothiazin-10-yl)-N,N-dimethyl-1-propanamine
3-(2-Chlorophenothiazin-10-yl)-N,N-dimethyl-propan-1-amine
3-(2-chloro-10H-Phenothiazin-10-yl)-N,N-dimethyl-1-propanamine
3-(2-chloro-10H-phenothiazin-10-yl)-N,N-dimethylpropan-1-amine
3-(2-chlorophenothiazin-10-yl)-N,N-dimethyl-propan-1-amine
3-(2-chlorophenothiazin-10-yl)-N,N-dimethylpropan-1-amine
34468-21-8
4560 R.P
4560 R.P.
4560 Rp hydrochloride
50-53-3
AB00051943
AC1L1EBT
AKOS001490972
Aminasine
Aminazin
Aminazine
Ampliactil
Amplicitil
Amplictil
BAS 00010434
BC 135
BPBio1_000273
BPBio1_001181
BSPBio_000247
BSPBio_002011
Bio1_000457
Bio1_000946
Bio1_001435
Biomol-NT_000020
C06906
C17H19ClN2S
CAS-69-09-0
CCRIS 3711
CHEBI:3647
CHEMBL71
CID2726
CPZ
Chlor-PZ
Chlor-Promanyl
Chlordelazine
Chlorderazin
Chloro-3 (dimethylamino-3 propyl)-10 phenothiazine
Chloro-3 (dimethylamino-3 propyl)-10 phenothiazine [French]
Chloropromazine
Chlorpromados
Chlorpromanyl
Chlorpromanyl (discontinued)
Chlorpromanyl-20
Chlorpromanyl-40
Chlorpromazin
Chlorpromazine
Chlorpromazine (USP/INN)
Chlorpromazine Hydrochloride Intensol
Chlorpromazine Tannate
Chlorpromazine [USAN:INN:BAN]
Chlorpromazinum
Chlorpromazinum [INN-Latin]
Clorpromazina
Clorpromazina [INN-Spanish]
Clorpromazina [Italian]
Contomin
Cromedazine
D00270
DB00477
DivK1c_000624
EINECS 200-045-8
Elmarin
Esmind
Fenactil
Fenaktyl
Fraction AB
HL 5746
HMS1920M03
HMS2089C12
HMS2091E06
HMS501P06
HSDB 3033
 
I14-6226
IDI1_000624
JHICC02042
KBio1_000624
KBio2_000622
KBio2_002312
KBio2_003190
KBio2_004880
KBio2_005758
KBio2_007448
KBio3_001231
KBio3_002792
KBioGR_000806
KBioGR_002312
KBioSS_000622
KBioSS_002314
L000182
LS-105361
Largactil
Largactil Liquid
Largactil Oral Drops
Largactilothiazine
Largactyl
Lopac-C-8138
Lopac0_000249
Megaphen
MolPort-001-727-953
N-(3-Dimethylaminopropyl)-3-chlorophenothiazine
NCGC00015273-01
NCGC00015273-02
NCGC00015273-03
NCGC00015273-14
NCGC00024409-04
NCGC00024409-05
NCGC00024409-06
NCGC00024409-07
NCGC00024409-08
NINDS_000624
NSC 167745
NSC167745
NSC17479
Novo-Chlorpromazine
Novomazina
Oprea1_110255
Phenactyl
Phenathyl
Phenothiazine hydrochloride
Plegomasine
Plegomazin
Prazilpromactil
Prestwick0_000064
Prestwick1_000064
Prestwick2_000064
Prestwick3_000064
Proma
Promactil
Promazil
Propaphen
Propaphenin
Prozil
Psychozine
QTL1_000021
SKF 2601-A
SKF 2601A
SKF-2601
SPBio_001111
SPBio_002168
SPECTRUM1500184
SR-01000000012-5
STK182870
STOCK1S-46588
Sanopron
Spectrum2_001156
Spectrum3_000346
Spectrum4_000283
Spectrum5_000717
Spectrum_000142
Thorazine
Thorazine (TN)
Thorazine Spansule
Thorazine Suppositories
Thorazine hydrochloride
Torazina
UNII-U42B7VYA4P
WLN: T C666 BN ISJ B3N1&1 EG
Wintermin
Z80
[3-(2-Chloro-phenothiazin-10-yl)-propyl]-dimethyl-amine
cMAP_000017
chlorpromazine
13tannic acidapproved, NutraceuticalPhase 42016
14Central Nervous System DepressantsPhase 4, Phase 3, Phase 2, Phase 113403
15Antipsychotic AgentsPhase 4, Phase 3, Phase 2, Phase 12401
16Hypnotics and SedativesPhase 42616
17Dopamine AgentsPhase 4, Phase 3, Phase 13836
18Tranquilizing AgentsPhase 4, Phase 3, Phase 2, Phase 14265
19Dopamine AntagonistsPhase 4, Phase 3, Phase 11093
20Psychotropic DrugsPhase 4, Phase 3, Phase 2, Phase 16430
21GABA AgentsPhase 41684
22Serotonin AgentsPhase 4, Phase 3, Phase 13156
23Neurotransmitter AgentsPhase 4, Phase 3, Phase 1, Phase 218340
24GABA-A Receptor AgonistsPhase 4115
25GABA AgonistsPhase 4163
26Serotonin AntagonistsPhase 4, Phase 3, Phase 11409
27
SerotoninPhase 4, Phase 3, Phase 1362750-67-95202
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
 
5-Hydroxy-tryptamine
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
Antemovis
DS substance
Enteramin
Enteramine
28Antidepressive Agents, Second-GenerationPhase 41311
29Antidepressive AgentsPhase 42736
30Cytochrome P-450 CYP2D6 InhibitorsPhase 4727
31Dopamine Uptake InhibitorsPhase 41331
32Cytochrome P-450 Enzyme InhibitorsPhase 43917
33Gastrointestinal AgentsPhase 4, Phase 18402
34Cholinesterase InhibitorsPhase 4592
35Cholinergic AgentsPhase 4, Phase 1, Phase 23992
36Autonomic AgentsPhase 4, Phase 110150
37Nootropic AgentsPhase 4, Phase 3, Phase 2716
38Peripheral Nervous System AgentsPhase 4, Phase 1, Phase 223689
39sultopridePhase 448
40Neurotransmitter Uptake InhibitorsPhase 4, Phase 3, Phase 13521
41Serotonin Uptake InhibitorsPhase 4, Phase 11587
42AntiemeticsPhase 4, Phase 14022
43Lithium carbonatePhase 4240554-13-2
44Antimanic AgentsPhase 4814
45Omega 3 Fatty AcidNutraceuticalPhase 4, Phase 21018
46PiracetamapprovedPhase 3, Phase 21757491-74-9
47
TetrabenazineapprovedPhase 31658-46-86018
Synonyms:
1,2,4,6,7,11b-hexahydro-3-Isobutyl-9,10-dimethoxy-2H-benzo[a]quinolizin-2-one
1,3,4,6,7,11b-Hexahydro-3-isobutyl-9,10-dimethoxy-2H-benzo(a)quinolizin-2-one
1,3,4,6,7,11b-Hexahydro-3-isobutyl-9,10-dimethoxy-2H-benzo[a]quinolizin-2-one
1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-Benzo[a]quinolizin-2-one
2-Oxo-3-isobutyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11bH-benzo[a]quinolizine
2-Oxo-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11-beta-hexahydro-2H-benzoquinolizine
2-Oxo-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11.beta.-hexahydro-2H-benzoquinolizine
2-oxo-3-Isobutyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11bh-benzo[a]quinolizine
2-oxo-3-Isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-benzoquinolizine
2H-Benzo(a)quinolizin-2-one, 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)- (9CI)
5-21-13-00178 (Beilstein Handbook Reference)
58-46-8
9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one
9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one
A2708/0115225
AC1L1LMF
AI3-52046
AKOS001681311
BRD-A47564106-001-01-8
BRN 0040090
C11168
CHEBI:293281
CHEMBL117785
CID6018
D08575
DB04844
EINECS 200-383-6
HMS1540E17
LS-40294
MLS001249426
MLS001249497
MLS003106727
MolPort-002-712-672
NCGC00160421-01
 
NCGC00160421-02
NSC 169886
NSC169886
NSC172187
Nitoman
Nitoman (TN)
Nitoman, Xenazine, Tetrabenazine
Oprea1_264344
Regulin
Ro 1-9569
Ro 1-9569/12
Rubigen
S1789_Selleck
SMR000718664
ST028814
STK678061
TBZ
TETRABENAZINE
TL8005032
Tetra benazin
Tetrabenazina
Tetrabenazina [INN-Spanish]
Tetrabenazina [inn-spanish]
Tetrabenazine (INN)
Tetrabenazine [INN:BAN]
Tetrabenazinum
Tetrabenazinum [INN-Latin]
Tetrabenazinum [inn-latin]
Tetrabenzaine
Tetrabenzine
TimTec1_002217
UNII-Z9O08YRN8O
WLN: T B666 DV GNTT&J E1Y1&1 LO1 MO1
Xenazine
Xenazine (TN)
tetra Benazin
48
Pyridoxineapproved, nutraceutical, vet_approvedPhase 3, Phase 218865-23-61054
Synonyms:
(5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate
12001-78-4
2-Methyl-3-hydroxy-4,5-bis(hydroxymethyl)pyridine
2-Methyl-3-hydroxy-4,5-di(hydroxymethyl)pyridine
2-Methyl-3-hydroxy-4,5-dihydroxymethyl-pyridin
2-Methyl-3-hydroxy-4,5-dihydroxymethyl-pyridin [German]
2-Methyl-3-hydroxy-4,5-dihydroxymethylpyridine
2-Methyl-4,5-bis(hydroxymethyl)-3-hydroxypyridine
2-methyl-3-hydroxy-4,5-bis(hydroxy-methyl) pyridine
2-methyl-3-hydroxy-4,5-dihydroxymethylpyridine
2-methyl-4,5-dimethylol-pyridin-3-ol
2B3E07D2-E4CC-4CC5-B085-6070BA01F9F0
3,4-Pyridinedimethanol, 5-hydroxy-6-methyl-, hydrochloride
3-Hydroxy-2-Picoline-4,5-dimethanol
3-Hydroxy-4,5-dihydroxymethyl-2-methylpyridine hydrochloride
3-Hydroxy-4,5-dimethylol-.alpha.-picoline hydrochloride
3-Hydroxy-4,5-dimethylol-alpha-picoline
3-Hydroxy-4,5-dimethylol-alpha-picoline hydrochloride
3-hydroxy-4,5-bis(hydroxymethyl)-2-methylpyridine
4,5-Bis(hydroxymethyl)-2-methyl-3-pyridinol
4,5-Bis(hydroxymethyl)-2-methylpyridin-3-ol hydrochloride
4,5-bis(hydroxymethyl)-2-methyl-3-pyridinol hydrochloride
4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol
4,5-bis(hydroxymethyl)-2-methylpyridine-3-ol
4-Deoxypyridoxine 5'-phosphate
47862_SUPELCO
5-Hydroxy-6-methyl-3,4-pyridinedicarbinol hydrochloride
5-Hydroxy-6-methyl-3,4-pyridinedimethanol
5-Hydroxy-6-methyl-3,4-pyridinedimethanol hydrochloride
5-Hydroxy-6-methyl-3,4-pyridinedimethanol, hydrochloride
58-56-0
58-56-0 (HCL)
58-56-0 (hydrochloride)
65-23-6
65-23-6 (Parent)
8059-24-3
85078-23-5
AC-12024
AC-14512
AC-907/25014218
AC1L1AMH
AC1L1LMI
AC1L2XK2
AC1Q22HP
AC1Q2G66
AC1Q3F63
AI3-19016
AIDS-006784
AIDS006784
AR-1A6363
AR-1J1632
Adermin hydrochloride
Adermine
Adermine hydrochloride
Aderomine hydrochloride
Aderoxin
Aderoxine
Alestrol
BB_NC-0050
BIDD:PXR0180
BPBio1_000646
BSPBio_000586
Becilan
Beesix
Benadon
Bonasanit
C00314
C8H11NO3
CAS-58-56-0
CBDivE_015627
CCRIS 1903
CHEBI:16709
CHEBI:30961
CHEMBL1200756
CHEMBL1364
CID104817
CID1054
CID6019
CPD0-1221
Campoviton 6
Cernevit-12
D02179
D025101
D08454
DB00165
EINECS 200-386-2
EINECS 200-603-0
EINECS 232-503-8
Godabion
Gravidox
HMS1569N08
HMS2093L07
HSDB 1212
Hexa-Betalin
Hexa-Betalin (R)
Hexa-betalin (TN)
Hexabetalin
Hexabione hydrochloride
 
Hexavibex
Hexermin
Hexermine
Hexobion
Hydoxin
I02-1897
I02-2297
KST-1A8556
LS-134393
LS-187072
LS-2332
MLS001074329
MLS002153915
MolPort-002-137-856
MolPort-002-319-991
MolPort-005-933-330
NCGC00016261-01
NCGC00164317-01
NCGC00180946-01
NSC 36225
NSC36225
NSC36225 (HCL)
Nestrex
Oprea1_061614
P0561
P4722_SIAL
P5669_SIGMA
P6280_SIGMA
P8666_SIGMA
P9755_SIAL
PN
PN HCl
PYRIDOXINE HYDROCHLORIDE
PYRIDOXINE HYDROCHLORIDE, U.S.P.
Paxadon
Piridossina
Piridossina [DCIT]
Piridoxina
Piridoxina [INN-Spanish]
Prestwick0_000623
Prestwick1_000623
Prestwick2_000623
Prestwick3_000623
Prestwick_925
Pydox
Pyridipca
Pyridox
Pyridoxin
Pyridoxin hydrochloride
Pyridoxine
Pyridoxine (INN)
Pyridoxine HCl
Pyridoxine Hydrochloride (B6)
Pyridoxine [INN:BAN]
Pyridoxine chloride
Pyridoxine hydrochloride (JP15/USP)
Pyridoxine hydrochloride [USAN:JAN]
Pyridoxine hydrogen chloride
Pyridoxine monohydrochloride
Pyridoxine, hydrochloride
Pyridoxine-HCl Microencapsulated
Pyridoxinium chloride
Pyridoxinum
Pyridoxinum [INN-Latin]
Pyridoxinum hydrochloricum
Pyridoxinum hydrochloricum (Hungarian)
Pyridoxol
Pyridoxol hydrochloride
Pyridoxol, hydrochloride
Pyridoxolum
Rodex
Rodex (R)
Rodex TD
SMP2_000230
SMR000674613
SPBio_002805
STK177324
STOCK1N-08684
Spondylonal
Tex Six T.R.
TimTec1_000657
UNII-68Y4CF58BV
UNII-KV2JZ1BI6Z
Vitamin B 6
Vitamin B6
Vitamin B6-hydrochloride
Vitamin V6
Vitamin V6 (TN)
Vitamin-?B6
Vitamin-?B6 hydrochloride
Vitaped
WLN: T6NJ B1 CQ D1Q E1Q &GH
ZINC00049154
ZINC21983293
bmse000288
c1302
component of Alestrol
nchembio.93-comp1
pyridoxine
vitamin B6
49
Folic Acidapproved, nutraceutical, vet_approvedPhase 3, Phase 2439259-30-36037
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
AI3-26387
AKOS000503224
ARONIS014410
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
Antianemia factor
Apo-Folic
BIDD:ER0563
BIDD:GT0641
BIF0608
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
FOL
Facid
Factor U
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
Folsaeure
 
Folsan
Folsaure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
Incafolic
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
LS-2157
Liver Lactobacillus casei factor
MLS001304016
MLS001335861
Millafol
Mission prenatal
Mittafol
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-Pteroyl-L-glutamic acid
N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
NINDS_000494
NSC 3073
Nifolin
Nifolin [Denmark]
Novofolacid
Novofolacid [Canada]
PGA
PGA (VAN)
Prestwick3_000627
Prestwick_230
PteGlu
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylglutamate
Pteroylglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
SMP2_000137
SMR000471860
SPBio_001357
SPECTRUM1502020
Serum Folate Level
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
Spectrum_001381
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin B9
Vitamin Bc
Vitamin Be
Vitamin M
bmse000299
folic acid
nchembio.108-comp10
50
Pyridoxalapproved, nutraceuticalPhase 3, Phase 218766-72-81050
Synonyms:
2-methyl-3-hydroxy-4-formyl-5-hydroxymethylpyridine
3-Hydroxy-5-(hydroxymethyl)-2-methylpyridine-4-carboxaldehyde
3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinecarboxaldehyde
 
3-hydroxy-5-(hydroxymethyl)-2-methylisonicotinaldehyde
3-hydroxy-5-(hydroxymethyl)-2-methylpyridine-4-carboxaldehyde
Piridoxal
Pyridoxal
Pyridoxaldehyde

Interventional clinical trials:

(show all 50)
idNameStatusNCT IDPhase
1Aripiprazole for Neuroleptic-Induced Tardive DyskinesiaUnknown statusNCT00837707Phase 4
2The Monitor of Serum Prolactin Level in a 3 Months Aripiprazole TrialUnknown statusNCT00468533Phase 4
3Risperidone and Zotepine in the Treatment of DeliriumUnknown statusNCT00622011Phase 4
4Treatment of Tardive Dyskinesia With GalantamineCompletedNCT00164242Phase 4
5Tardive Dyskinesia and Cognitive FunctionCompletedNCT00926965Phase 4
6Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Tardive DyskinesiaCompletedNCT00621998Phase 4
7Ethyl-Eicosapentaenoic Acid and Tardive DyskinesiaCompletedNCT00114595Phase 4
8The Pharmacogenetic Study , Readiness to Change, and Pharmacological Intervention for Smoking Cessation in SchizophreniaCompletedNCT00495352Phase 4
9Efficacy and Tolerability of Switching to Ziprasidone From Other AntipsychoticsCompletedNCT00458211Phase 4
10Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic FeaturesRecruitingNCT00202293Phase 4
11A Phase 3 Study of NBI-98854 for the Treatment of Tardive DyskinesiaCompletedNCT02274558Phase 3
12Piracetam for Treatment Tardive DyskinesiaCompletedNCT00190008Phase 3
13Extract of Ginkgo Biloba and Tardive DyskinesiaCompletedNCT00672373Phase 3
14Addressing Involuntary Movements in Tardive DyskinesiaCompletedNCT02291861Phase 3
15Aim to Reduce Movements in Tardive DyskinesiaCompletedNCT02195700Phase 2, Phase 3
16Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive DyskinesiaCompletedNCT02405091Phase 3
17Levetiracetam Treatment of Tardive DyskinesiaCompletedNCT00291213Phase 3
18A Study of the Long-term Safety and Tolerability and the Long-term Effectiveness of Extended-release Oral Paliperidone in Patients Diagnosed With SchizophreniaCompletedNCT00210769Phase 3
19Study to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone.CompletedNCT00399698Phase 3
20Akathisia (Restless Legs Syndrome) in People With Schizophrenia and Mental RetardationCompletedNCT00065286Phase 3
21Xenazine in Late Dyskinetic Syndrome With NeurolepticsRecruitingNCT01543321Phase 3
22Reducing Involuntary Movements in Tardive DyskinesiaActive, not recruitingNCT02198794Phase 3
23D-Serine Treatment For Tardive DyskinesiaActive, not recruitingNCT01804920Phase 2, Phase 3
24Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive DyskinesiaEnrolling by invitationNCT02736955Phase 3
25A Phase 2/3 Study of MT-5199 for the Treatment in Patients With Tardive DyskinesiaNot yet recruitingNCT03176771Phase 2, Phase 3
26Pyridoxal Kinase Activity in Tardive DyskinesiaWithdrawnNCT01908452Phase 3
27Efficacy of Docosahexaenoic Acid on Tardive DyskinesiaUnknown statusNCT00621634Phase 2
28Efficacy and Safety of Deep Brain Stimulation (DBS) of the Pallidal (GPi) in Patients With Tardive DystoniaUnknown statusNCT00331669Phase 2
29NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective DisorderCompletedNCT01393600Phase 2
30Efficacy and Safety of NBI-98854 in Subjects With Tardive DyskinesiaCompletedNCT01267188Phase 2
31NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)CompletedNCT01688037Phase 2
32NBI-98854 Dose Titration Study for the Treatment of Tardive DyskinesiaCompletedNCT01733121Phase 2
33A Phase 2 Trial Evaluating SNC-102 in Drug-Induced Tardive DyskinesiaCompletedNCT02064010Phase 2
34Levetiracetam in the Treatment of Neuroleptic-induced Tardive DyskinesiaCompletedNCT00175955Phase 2
35Heart Rate Variability in Response to Metformin ChallengeCompletedNCT02500628Phase 2
36Efficacy Study of Panax Ginseng to Boost Antipsychotics Effects in SchizophreniaCompletedNCT00401089Phase 1, Phase 2
37Transcutaneous Non-invasive Vagus Nerve Stimulation (t-VNS) in the Treatment of SchizophreniaCompletedNCT01176721Phase 2
38Dysport for the Treatment of OMDActive, not recruitingNCT01921270Phase 1, Phase 2
39Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive DyskinesiaTerminatedNCT00917293Phase 2
40Movement Disorders Caused by Antipsychotic Drugs in Older PatientsCompletedNCT00255879Phase 1
41Melatonin Treatment for Tardive Dyskinesia in SchizophreniaCompletedNCT01391390
42The Assessment of Movement Disorders Utilizing Live Two-Way VideoCompletedNCT01467089
43CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar IllnessCompletedNCT01149551
44Effect of Activity on Sleep of Cognitively-Impaired VeteransCompletedNCT00013182
45Real‐World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic AgentsRecruitingNCT03062033
46Validation of the Implantation of a New Electrode for the Treatment of DystoniaRecruitingNCT02509338
47ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement DisordersRecruitingNCT02252380
48Repetitive Transcranial Magnetic Stimulation for the Treatment of the Tardive Dyskinesia.Not yet recruitingNCT02840760
49Sarizotan in the Treatment of Neuroleptic-induced Tardive DyskinesiaTerminatedNCT00310661
50Deep Brain Stimulation for Patients With Tardive Dyskinesia and or DystoniaTerminatedNCT02524886

Search NIH Clinical Center for Tardive Dyskinesia

Genetic Tests for Tardive Dyskinesia

About this section

Genetic tests related to Tardive Dyskinesia:

id Genetic test Affiliating Genes
1 Tardive Dyskinesia27

Anatomical Context for Tardive Dyskinesia

About this section

MalaCards organs/tissues related to Tardive Dyskinesia:

36
Tongue, Eye, Brain, Globus pallidus, Testes, Cortex, Endothelial

Publications for Tardive Dyskinesia

About this section

Articles related to Tardive Dyskinesia:

(show top 50)    (show all 602)
idTitleAuthorsYear
1
Clozapine Treatment of Olanzapine-induced Tardive Dyskinesia: A Case Report. (28072646)
2017
2
Propranolol therapy for Tardive dyskinesia: A retrospective examination. (27622970)
2016
3
Tardive Dyskinesia, Oral Parafunction, and Implant-Supported Rehabilitation. (28050290)
2016
4
Two Cases of Iloperidone-Related Tardive Dyskinesia. (27749678)
2016
5
Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 3: Clinical Trial Data. (27138080)
2016
6
Forgotten but not gone: new developments in the understanding and treatment of tardive dyskinesia. (28044943)
2016
7
Markedly Reduced Thermal Pain Perception in a Schizoaffective Patient with Tardive Dyskinesia. (27144045)
2016
8
Association between DBH 19bp insertion/deletion polymorphism and cognition in schizophrenia with and without tardive dyskinesia. (27776953)
2016
9
A Case of Aripiprazole-Induced Tardive Dyskinesia with Dramatic Evolution. (27818825)
2016
10
Long-term efficacy and tolerability of bilateral pallidal stimulation to treat tardive dyskinesia. (26791148)
2016
11
Report: Protective effects of rice bran oil in haloperidol-induced tardive dyskinesia and serotonergic responses in rats. (27592482)
2016
12
Successful Management of Tardive Dyskinesia with Quetiapine and Clonazepam in a Patient of Schizophrenia with Type 2 Diabetes Mellitus. (27121435)
2016
13
Laughter therapy in a geriatric patient with treatment-resistant depression and comorbid tardive dyskinesia. (27164922)
2016
14
Likelihood of mechanistic roles for dopaminergic, serotonergic and glutamatergic receptors in tardive dyskinesia: A comparison of genetic variants in two independent patient populations. (27127627)
2016
15
Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 4: Case Report Data. (27123800)
2016
16
Co-morbid obsessive compulsive and hypochondriac disorders complicated by tardive dyskinesia in a Nigerian man. (26755234)
2016
17
Association study of MiRSNPs with schizophrenia, tardive dyskinesia and cognition. (27106592)
2016
18
Lipoic acid and haloperidol-induced vacuous chewing movements: Implications for prophylactic antioxidant use in tardive dyskinesia. (27565433)
2016
19
Pharmacogenetics of tardive dyskinesia: an updated review of the literature. (27469238)
2016
20
Drug-Induced Dyskinesia, Part 2: Treatment of Tardive Dyskinesia. (27091214)
2016
21
Paliperidone Palmitate-Associated Severe Refractory Tardive Dyskinesia With Tardive Dystonia: Management and Six-Months Follow-Up. (27269958)
2016
22
Divalproex sodium leading to sustained significant improvement in tardive dyskinesia in a patient with bipolar disorder. (26985118)
2016
23
Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 2: Preclinical and Early Phase Human Proof of Concept Studies. (26813487)
2016
24
Ginkgo biloba and vitamin E ameliorate haloperidol-induced vacuous chewingmovement and brain-derived neurotrophic factor expression in a rat tardive dyskinesia model. (27264436)
2016
25
Striatal cholinergic interneurons and D2 receptor-expressing GABAergic medium spiny neurons regulate tardive dyskinesia. (27658674)
2016
26
Extract of Ginkgo biloba for Tardive Dyskinesia: Meta-analysis of Randomized Controlled Trials. (26979525)
2016
27
High dose pyridoxine for the treatment of tardive dyskinesia: clinical case and review of literature. (27141296)
2016
28
Tardive dyskinesia occurring in a young woman after withdrawal of an atypical antipsychotic drug. (26492119)
2015
29
Altered IL-2, IL-6 and IL-8 serum levels in schizophrenia patients with tardive dyskinesia. (25600548)
2015
30
Utilizing the concept of geste antagoniste for conservative management of oro-mandibular tardive dyskinesia: a case report and mini-review. (26293144)
2015
31
Tardive dyskinesia and covert dyskinesia with Aripiprazole: a case series. (26391425)
2015
32
Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia. (25866243)
2015
33
Cytochrome P450 1A2 co-determines neuroleptic load and may diminish tardive dyskinesia by increased inducibility. (25602162)
2015
34
Comparing the risk of tardive dyskinesia in older adults with first-generation and second-generation antipsychotics: a systematic review and meta-analysis. (26679687)
2015
35
Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder: Part 1. (26348804)
2015
36
Valbenazine granted breakthrough drug status for treating tardive dyskinesia. (25809133)
2015
37
Identification and management of tardive dyskinesia: A case series and literature review. (26216578)
2015
38
Mn-superoxide dismutase activity is associated with orofacial involuntary movements in schizophrenia patients with tardive dyskinesia. (25572310)
2015
39
Lifelong Rodent Model of Tardive Dyskinesia-Persistence After Antipsychotic Drug Withdrawal. (26472552)
2015
40
The association between COMT Val158Met gene polymorphism and antipsychotic-induced tardive dyskinesia risk. (26398367)
2015
41
Efficacy of aripiprazole in antidepressants-induced tardive dystonia and tardive dyskinesia: a case report. (26057318)
2015
42
Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in Phase II and Phase III clinical trials. (26166007)
2015
43
Erratum for Vinuela A, Kang UJ. Reversibility of tardive dyskinesia syndrome. Tremor Other Hyperkinet Mov. 2014; 4. doi: 10.7916/D86Q1VXZ. (26417537)
2015
44
A quantitative measure of handwriting dysfluency for assessing tardive dyskinesia. (25679121)
2015
45
NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study. (26346941)
2015
46
A case of tardive dyskinesia in the last weeks of life. (26095485)
2015
47
Tardive dyskinesia and tardive dystonia with second-generation antipsychotics in non-elderly schizophrenic patients unexposed to first-generation antipsychotics: a cross-sectional and retrospective study. (25485636)
2015
48
Late-onset Quetiapine-related Tardive Dyskinesia Side Effects in a Patient with Psychotic Depression. (25191509)
2014
49
Reversibility of tardive dyskinesia syndrome. (25493205)
2014
50
BDNF Val66Met polymorphism and antipsychotic-induced tardive dyskinesia occurrence and severity: A meta-analysis. (24411528)
2014

Variations for Tardive Dyskinesia

About this section

Expression for genes affiliated with Tardive Dyskinesia

About this section
Search GEO for disease gene expression data for Tardive Dyskinesia.

Pathways for genes affiliated with Tardive Dyskinesia

About this section

Pathways related to Tardive Dyskinesia according to GeneCards Suite gene sharing:

(show all 11)
idSuper pathwaysScoreTop Affiliating Genes
19.7NQO1, SOD2
29.7DRD2, DRD3
3
Show member pathways
9.3CYP1A2, NQO1
49.3CYP1A2, NQO1
59.3CYP1A2, NQO1
6
Show member pathways
9.2DRD2, DRD3, HTR2A
79.0CYP1A2, CYP2D6
8
Show member pathways
9.0CYP1A2, CYP2D6
9
Show member pathways
8.7CYP1A2, CYP2D6, NQO1
10
Show member pathways
8.7CYP1A2, CYP2D6, NQO1
118.3CYP1A2, CYP2D6, NQO1, SOD2

GO Terms for genes affiliated with Tardive Dyskinesia

About this section

Biological processes related to Tardive Dyskinesia according to GeneCards Suite gene sharing:

(show all 45)
idNameGO IDScoreTop Affiliating Genes
1acid secretionGO:004671710.4DRD2, DRD3
2adenylate cyclase-inhibiting dopamine receptor signaling pathwayGO:000719510.4DRD2, DRD3
3arachidonic acid secretionGO:005048210.4DRD2, DRD3
4dopamine metabolic processGO:004241710.4DRD2, DRD3
5dopamine receptor signaling pathwayGO:000721210.4DRD2, DRD3
6G-protein coupled receptor internalizationGO:000203110.4DRD2, DRD3
7negative regulation of adenylate cyclase activityGO:000719410.4DRD2, DRD3
8negative regulation of blood pressureGO:004577610.4DRD2, DRD3
9negative regulation of dopamine receptor signaling pathwayGO:006016010.4DRD2, DRD3
10negative regulation of protein kinase B signalingGO:005189810.4DRD2, DRD3
11negative regulation of protein secretionGO:005070910.4DRD2, DRD3
12positive regulation of cytokinesisGO:003246710.4DRD2, DRD3
13positive regulation of renal sodium excretionGO:003581510.4DRD2, DRD3
14prepulse inhibitionGO:006013410.4DRD2, DRD3
15regulation of cAMP metabolic processGO:003081410.4DRD2, DRD3
16removal of superoxide radicalsGO:001943010.4NQO1, SOD2
17regulation of dopamine uptake involved in synaptic transmissionGO:005158410.4DRD2, DRD3
18regulation of locomotion involved in locomotory behaviorGO:009032510.4DRD2, DRD3
19response to amphetamineGO:000197510.4DRD2, DRD3
20response to cocaineGO:004222010.4DRD2, DRD3
21response to histamineGO:003477610.3DRD2, DRD3
22response to axon injuryGO:004867810.3DRD2, SOD2
23negative regulation of synaptic transmission, glutamatergicGO:005196710.3DRD2, HTR2A
24response to morphineGO:004327810.3DRD2, DRD3
25superoxide metabolic processGO:000680110.3NQO1, SOD2
26synaptic transmission, dopaminergicGO:000196310.3DRD2, DRD3
27release of sequestered calcium ion into cytosolGO:005120910.2DRD2, HTR2A
28visual learningGO:000854210.2DRD2, DRD3
29temperature homeostasisGO:000165910.1DRD2, HTR2A
30response to ethanolGO:004547110.0DRD2, DRD3, NQO1
31locomotory behaviorGO:000762610.0DRD2, DRD3, SOD2
32hydrogen peroxide biosynthetic processGO:00506659.9CYP1A2, SOD2
33agingGO:00075689.9HTR2A, NQO1, SOD2
34behavioral response to cocaineGO:00481489.9DRD2, DRD3, HTR2A
35regulation of dopamine secretionGO:00140599.9DRD2, DRD3, HTR2A
36response to immobilization stressGO:00359029.8CYP1A2, SOD2
37alkaloid metabolic processGO:00098209.8CYP1A2, CYP2D6
38drug catabolic processGO:00427379.8CYP1A2, CYP2D6
39drug metabolic processGO:00171449.8CYP1A2, CYP2D6
40heterocycle metabolic processGO:00464839.8CYP1A2, CYP2D6
41monoterpenoid metabolic processGO:00160989.8CYP1A2, CYP2D6
42oxidative demethylationGO:00709899.7CYP1A2, CYP2D6
43oxidation-reduction processGO:00551149.0CYP1A2, CYP2D6, NQO1, SOD2
44xenobiotic metabolic processGO:00068058.7CYP1A2, CYP2D6, NQO1
45response to drugGO:00424938.5CYP1A2, DRD2, DRD3, HTR2A, SOD2

Molecular functions related to Tardive Dyskinesia according to GeneCards Suite gene sharing:

(show all 9)
idNameGO IDScoreTop Affiliating Genes
1dopamine bindingGO:003524010.4DRD2, DRD3
2dopamine neurotransmitter receptor activityGO:000495210.4DRD2, DRD3
3dopamine neurotransmitter receptor activity, coupled via Gi/GoGO:000159110.4DRD2, DRD3
4aromatase activityGO:00703309.7CYP1A2, CYP2D6
5superoxide dismutase activityGO:00047849.7NQO1, SOD2
6oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenGO:00167129.5CYP1A2, CYP2D6
7drug bindingGO:00081449.2CYP2D6, DRD2, DRD3, HTR2A
8oxidoreductase activityGO:00164918.7CYP1A2, CYP2D6, NQO1, SOD2
9oxygen bindingGO:00198258.7CYP1A2, CYP2D6, SOD2

Sources for Tardive Dyskinesia

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet